GMW Clinical Psychologist Leads World First Bipolar At-Risk Trial | News and Events

Graphic device

Improving lives

GMW Clinical Psychologist Leads World First Bipolar At-Risk Trial

BART Dr Sophie Paker

A brand new clinical research trial is currently underway at Greater Manchester West Mental Health NHS Foundation Trust (GMW) led by Dr Sophie Parker.

The Bipolar At-Risk Trial (BART) is a world first and has been awarded funding from the National Institute for Health Research (NIHR). It aims to

investigate whether Cognitive Behavioural Therapy (CBT) is an acceptable, feasible and potentially effective treatment option for people who have been identified as being at risk of developing bipolar disorder.

The research team have already recruited 49 people to take part in the study and are following their progress over a 12-month period. Anyone aged 16-25 who is having difficulty with mood swings is being invited to take part.

The research team have had amazing support from clinical services at GMW and have recently awarded 3 teams with certificates for their contributions to the research.

Matt Riley (pictured below left), a psychological therapist at the Salford EDIT service was awarded the top individual referrer certificate. Kendra Ainley, team leader at Single Point of Access (pictured below centre) accepted the certificate on behalf of her team for being one of our top three referrers. Salford Psychology Primary Care Service Triage Team were also awarded a certificate for being one of our top referrers, with Natalie Green, Helen Stafford and Alison Harris accepting the award (pictured below right).

staff

Please contact the research team if you know anyone who may want to take part:
Lydia Pearson on 0161 358 1863/ 07827 903 300 or Emmeline Joyce on 0161 358 0837 / 07584 206 815 or Sophie Parker on 0161 358 1395 / 07767 755 790 (Senior Clinical Psychologist & Project Lead).

We place cookies on your computer to help make this website better. You can at any time read our privacy policy to find out more. By using this site we will assume that you are happy to continue.

Change cookie settings: